The Breast Cancer Research Foundation
Medical Symposium held at the Waldorf-Astoria, NYC on Tuesday, October 16, 2007

Evelyn H. Lauder
Founder and Chairman, The Breast Cancer Research Foundation


Panel Moderator:

Larry Norton, MD
Chairman, BCRF Executive Board of Scientific Advisors
Deputy Physician-in-Chief of Memorial Hospital; Director of Breast Cancer Programs, Memorial Sloan-Kettering Cancer Center, New York, NY


Panelists:

Robert Benezra, PhD
Member, Department of Cell Biology; Memorial Sloan-Kettering Cancer Center, New York, NY

Nancy E. Davidson, MD
Member, BCRF Executive Board of Scientific Advisors
President, American Society of Clinical Oncology (ASCO)
Professor and Breast Cancer Research Chair in Oncology; Director of the Breast Cancer Research Program; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

Laura J. Esserman, MD, MBA
Professor of Surgery and Radiology; Director, Carol Franc Buck Breast Care Center; UCSF Comprehensive Cancer Center, University of California/San Francisco, San Francisco, CA

Judah Folkman, MD
Director, Vascular Biology Program, Children's Hospital and Harvard Medical School, Boston, MA

George W. Sledge, MD
2007 BCRF Jill Rose Awardee
Ballve Professor of Medicine and Pathology, Indiana University School of Medicine, Indianapolis, IN

Q&A Topics

1) Relationship between women who carry the BRCA-1 and/or BRCA-2 gene and Breast and Ovarian cancer
Introduction by: Larry Norton, MD (Moderator)
Response by: Mary-Claire King, PhD
American Cancer Society Professor, Departments of Medicine and Genome Sciences
University of Washington, Seattle, WA

2) Breast Cancer Screening: Mammography vs. MRI
Response by: Laura J. Esserman, MD, MBA (Panelist)
Judy Garber, MD, MPH (from the audience)
Member, BCRF Scientific Advisory Committee
Director, Cancer Risk & Prevention; Department of Adult Oncology
Dana-Farber Cancer Institute, Brigham & Women's Hospital, Boston, MA

3) Triple negative breast cancer (when pathology states that the tumor is estrogen receptor-negative, progesterone receptor-negative and HER2-negative.)
Response by: Nancy E. Davidson, MD (Panelist)

4) Translational Breast Cancer Research Consortium
Response by: Nancy E. Davidson, MD (Panelist)

5) Estrogen-receptor negative breast cancer
Response from the audience by:
Joyce Slingerland, MD, PhD, FRCP(C)
Director, Braman Family Breast Cancer Institute, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL

6) Breast cancer as more than one disease
Response by:
Charles M. Perou, PhD
Assoc. Professor of Genetics & Pathology, Carolina Center for Genome Sciences
University of North Carolina, Chapel Hill, NC
Laura J. Esserman, MD (Panelist)
George W. Sledge, MD (Panelist)

7) The role of Taxol therapy, based on recent clinical trials
Response by: Daniel F. Hayes, MD
Professor of Medicine, Director, Breast Oncology Program, University of Michigan, Ann Arbor, MI
Comments by: Larry Norton, MD (Moderator)

8) The role of Vitamin D and sun exposure
Response by: Walter C. Willett, MD, DrPH
Chair, Department of Nutrition; Professor of Epidemiology and Nutrition; Professor of Medicine, Harvard Medical School, Harvard School of Public Health, Boston, MA

9) More funding needed
Response by: Larry Norton, MD (Moderator)

10) Targeted Therapies
Response by:
Robert Benezra, PhD (Panelist)
Judah Folkman, MD (Panelist)
Laura J. Esserman, MD (Panelist)
Comments by:
Larry Norton, MD (Moderator)